To understand cardiac and pulmonary function in patients with covid-19 in India
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2021/01/030604
- Lead Sponsor
- Dr Anoop Shah
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
COVID-19 positive patients
1-COVID-19 positive
2-Ideally 2 weeks withina positive test (but can be extended to 4 weeks)
3-Symptoms suggestive of an acute respiratory viral illness
Positive controls
1-COVID-19 negative (PCR andserology)
2-Symptoms suggestive of an acute respiratory viral illness
Negative controls
1-COVID-19 negative (PCR andserology)
2-Absence of symptoms of acute respiratory viral illness
1-Prior diagnosis of myocardial infarction
2-Prior diagnosis of a non-ischaemic cardiomyopathy
3-Patients requiring invasive or non-invasive ventilation
4-Previous coronary revascularisation or cardiac surgery
5-Patient inability to undergo CT or CMR scanning, due to severe renal failure (estimated glomerular filtration rate <30 mL/min) or major allergy to iodinated contrast media /gadolinium
6-Pregnancy or breast feeding
7-Inability to give informed consent
8-Contraindication to imaging, example metal fragments in the eye
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method A. Identify the proportion of patients with biochemical evidence of myocardial injury or strain <br/ ><br>i.Presence of elevated cardiac troponin or NTproBNP concentrations <br/ ><br>B. Identify the presence of atherosclerotic disease CTCA <br/ ><br>i.Presence of obstructive coronary artery disease on CTCA 70% <br/ ><br>C.Identify myocardial disease <br/ ><br>D.Identify vascular inflammation PET scan <br/ ><br>E. Describe and quantify degree of pulmonary fibrosis <br/ ><br>F. Describe the change across cases and positive controlsTimepoint: 6 Months <br/ ><br>
- Secondary Outcome Measures
Name Time Method B. Identify the presence of atherosclerotic disease CTCA <br/ ><br>i.Presence of obstructive coronary artery disease on CTCA 70% <br/ ><br>C.Identify myocardial disease <br/ ><br>D.Identify vascular inflammation PET scan <br/ ><br>E. Describe and quantify degree of pulmonary fibrosis <br/ ><br>F. Describe the change across cases and positive controlsTimepoint: 6 months